Cyteir Therapeutics (Cyteir Therapeutics) Gross Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Cyteir Therapeutics's Gross Profit for the three months ended in Sep. 2023 was $0.00 Mil. Cyteir Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Cyteir Therapeutics's Gross Margin % for the quarter that ended in Sep. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Cyteir Therapeutics's Gross Margin % or its related term are showing as below:

CYTT's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 60.9
* Ranked among companies with meaningful Gross Margin % only.

Cyteir Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Cyteir Therapeutics was 0.00% per year.

Cyteir Therapeutics Gross Margin % Historical Data

The historical data trend for Cyteir Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics Gross Margin % Chart

Cyteir Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Gross Margin %

Cyteir Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Gross Margin %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Cyteir Therapeutics's Gross Margin %

For the Biotechnology subindustry, Cyteir Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyteir Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Cyteir Therapeutics's Gross Margin % falls into.

Cyteir Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Cyteir Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )	=	Gross Profit (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

Cyteir Therapeutics's Gross Margin for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )	=	Gross Profit (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Cyteir Therapeutics (OTCPK:CYTT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cyteir Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Cyteir Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421

Website

https://www.cyteir.com

Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness	officer: General Counsel	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey	director	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong	director	69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven	10 percent owner	BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl	10 percent owner	28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken	director	128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421